XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue from Contracts with Customers (Tables)
9 Months Ended
Sep. 30, 2022
Revenue from Contracts with Customers  
Summary of product revenue provision and allowance

    

Trade

Rebates and

Product

Allowances and

Incentives (1)

Returns (2)

Chargebacks (3)

Balance at December 31, 2021

$

142,379

$

54,617

$

13,226

Acquired from BDSI

38,074

18,187

7,575

Provision related to current period sales

368,880

26,508

94,859

Changes in estimate related to prior period sales

(304)

(838)

(580)

Credits/payments made

(385,298)

(20,987)

(93,946)

Balance at September 30, 2022

$

163,731

$

77,487

$

21,134

    

    

Trade

Rebates and

Product

Allowances and

Incentives (1)

Returns (2)

Chargebacks (3)

Balance at December 31, 2020

$

132,775

$

23,779

$

19,055

Provision related to current period sales

273,576

13,750

63,279

Changes in estimate related to prior period sales

(434)

6

Credits/payments made

(261,210)

(3,473)

(58,213)

Credits expired (4)

12,960

Balance at September 30, 2021

$

144,707

$

47,016

$

24,127

(1)Provisions for rebates and incentives includes managed care rebates, government rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Consolidated Balance Sheets.
(2)Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Consolidated Balance Sheets.
(3)Provisions for trade allowances and chargebacks include fees for distribution service fees, prompt pay discounts, and chargebacks. Trade allowances and chargebacks are deducted from gross revenue at the time revenues are recognized and are recorded as a reduction to accounts receivable in the Company’s Consolidated Balance Sheets.
(4)During the nine months ended September 30, 2021, $12,960 of previously credited product returns were no longer eligible for credit under the Company’s returns policy as the product was not received as of the period end.
Schedule of disaggregation of revenue

Three Months Ended September 30,

Nine Months Ended September 30,

2022

2021

2022

2021

Belbuca

$

38,802

$

$

84,413

$

Xtampza ER

38,859

    

30,016

103,567

98,448

Nucynta IR

27,274

29,086

83,163

88,853

Nucynta ER

17,133

19,741

53,473

62,205

Symproic

3,580

7,740

Elyxyb

218

352

Other

1,147

1,605

Total product revenues, net

$

127,013

$

78,843

$

334,313

$

249,506